Nanjing Pharmaceutical Group Company Limited Class A

Nanjing Pharmaceutical Group Company Limited Class A

SSSE:600713
5.19
CNY
-0.04
(-0.76%)
0.57EPS
10.17P/E
6.54BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Nanjing Pharmaceutical Group Company Limited Class A carries a market capitalization of 6.54B, placing it among publicly traded companies globally. Its enterprise value stands at 15.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.54B
Enterprise Value15.32B

Share Statistics

As of September 30, 2026, Nanjing Pharmaceutical Group Company Limited Class A has 1.31B shares outstanding.

Shares Outstanding1.31B

Valuation Ratios

As of September 30, 2026, Nanjing Pharmaceutical Group Company Limited Class A trades at a trailing price-to-earnings ratio of 10.17. The price-to-sales ratio is 0.12, and the price-to-book ratio stands at 0.90.

PE Ratio10.17
PS Ratio0.12
PB Ratio0.90
P/TBV Ratio0.99

Enterprise Valuation

As of September 30, 2026, Nanjing Pharmaceutical Group Company Limited Class A trades at an EV/EBITDA multiple of 12.36 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.36 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 15.32B versus a market cap of 6.54B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.28
EV / EBITDA12.36
EV / EBIT12.36

Financial Position

As of September 30, 2026, Nanjing Pharmaceutical Group Company Limited Class A maintains a current ratio of 1.44, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 106.04, indicating elevated leverage, while an interest coverage ratio of 4.05 demonstrates adequate ability to service its debt obligations.

Current Ratio1.44
Quick Ratio0.08
Debt / Equity106.04
Debt / EBITDA7.49
Interest Coverage4.05

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 11.82M in revenue per employee across its workforce of 4,697.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee11.82M
Employee Count4,697.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Nanjing Pharmaceutical Group Company Limited Class A recorded 361.55M in income tax expense. That works out to an effective tax rate of 29.90, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.21B, leaving 638.08M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax361.55M
Effective Tax Rate29.90

Stock Price Statistics

CNY

As of the close on November 17, 2026, Nanjing Pharmaceutical Group Company Limited Class A's stock has declined approximately 1.33% over the past 52 weeks. The 50-day moving average sits at 5.15, while the 200-day moving average is 5.26.

52-Week Price Change-1.33%
50-Day Moving Average5.15
200-Day Moving Average5.26

Income Statement

CNY

Over the twelve months ended September 30, 2026, Nanjing Pharmaceutical Group Company Limited Class A generated 55.52B in revenue and converted that into 638.08M in net income, yielding earnings per share of 0.57. EBITDA reached 1.24B, while operating income came in at 1.60B.

Revenue55.52B
Gross Profit3.49B
Operating Income1.60B
Pretax Income1.21B
Net Income638.08M
EBITDA1.24B
EBIT1.24B
Earnings Per Share (EPS)0.57

Balance Sheet

CNY

As of September 30, 2026, Nanjing Pharmaceutical Group Company Limited Class A holds 2.00B in cash and equivalents against 9.29B in total debt, resulting in a net debt position of 7.14B. Total book value stands at 7.26B, with working capital of 10.71B providing operational flexibility.

Cash & Cash Equivalents2.00B
Total Debt9.29B
Net Debt7.14B
Equity (Book Value)7.26B
Book Value Per Share5.55
Working Capital10.71B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-215.08M

Margins

Over the twelve months ended September 30, 2026, Nanjing Pharmaceutical Group Company Limited Class A posted a gross margin of 6.29, reflecting its pricing power and cost economics. The operating margin of 2.88 and net profit margin of 1.15 provide insight into operational efficiency.

Gross Margin6.29
Operating Margin2.88
Pretax Margin2.18
Profit Margin1.15
EBITDA Margin2.23

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Nanjing Pharmaceutical Group Company Limited Class A paid dividends of 0.45 per share. The dividend payout ratio of 55.67 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -28.85, meaning Nanjing Pharmaceutical Group Company Limited Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.45
Payout Ratio55.67
Shareholder Yield-28.85

Stock Splits

Nanjing Pharmaceutical Group Company Limited Class A's most recent stock split took place on July 8, 2011 with a 1:2 split ratio.

Last Split Date7/8/2011
Split Ratio1:2

Scores

As of September 30, 2026, Nanjing Pharmaceutical Group Company Limited Class A has an Altman Z-Score of 2.18, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.18